Skip to main content

Characterizing the Tumor Microenvironment through Immunophenotyping and Spatial Biology using Ultivue 8-plex Immunofluorescence Technology on the BOND RX Research Stainer

Robyn Broad, PhD, Senior Scientist, Tumour Profiling, Translational Sciences, Adaptimmune Limited, UK

RELATED PRODUCTS
SHARE

CONTACT YOUR RESEARCH EXPERT

Multiplex immunofluorescence (mIF) assays offer the advantage of preserving the architectural features of the tumor microenvironment and revealing the spatial relationships between tumor cells and immune cells that are present.

Using custom-designed Ultivue 8-plex kits on the BOND RX system by Leica Biosystems, it enables the definition of the T cell phenotypes spatially and quantitively. This is especially important in treatment response monitoring and TME infiltration assessment in immunotherapy clinical programs at Adaptimmune where next generation SPEAR-T cell have been developed using Adaptimmune’s affinity-enhanced tumor antigen targeting TCR technology.

For Research Use Only. Not for use in diagnostic procedures.

El contenido de Leica Biosystems Knowledge Pathway está sujeto a las condiciones de uso del sitio web de Leica Biosystems, disponibles en: Aviso legal. El contenido, incluidos los webinars o seminarios web, los recursos de formación y los materiales relacionados, está destinado a proporcionar información general sobre temas concretos de interés para los profesionales de la salud y no está destinado a ser, ni debe interpretarse como asesoramiento médico, normativo o jurídico. Los puntos de vista y opiniones expresados en cualquier contenido de terceros reflejan los puntos de vista y opiniones personales de los ponentes/autores y no representan ni reflejan necesariamente los puntos de vista ni opiniones de Leica Biosystems, sus empleados o sus agentes. Cualquier enlace incluido en el contenido que proporcione acceso a recursos o contenido de terceros se proporciona únicamente por comodidad.

Para el uso de cualquier producto, debe consultarse la documentación correspondiente del producto, incluidas las guías de información, los prospectos y los manuales de funcionamiento.

Copyright © 2022 Leica Biosystems division of Leica Microsystems, Inc. y sus filiales de Leica Biosystems. Todos los derechos reservados. LEICA y el logotipo de Leica son marcas comerciales registradas de Leica Microsystems IR GmbH.

About the presenter

Robyn Broad, PhD, Senior Scientist, Tumour Profiling, Translational Sciences, Adaptimmune Limited, UK

Robyn Broad completed her undergraduate degree in Biochemistry at the University of Manchester, UK in 2014. During her undergraduate degree, she had the opportunity of undertaking a placement year, which she completed at MedImmune, Cambridge UK. During her time at MedImmune, Robyn worked in both the phage display team and histology group, producing, and identifying IHC compatible antibodies for targets where commercial antibodies were not currently available. Following completion of her undergraduate degree, Robyn received her MSc in Cancer Research and Molecular Biomedicine again from the University of Manchester and received her PhD from the School of Medicine at the University of Leeds in 2019, where she investigated the role of cancer-associated fibroblasts on chemoresistance in triple negative breast cancer. Since 2018, Robyn has worked at Adaptimmune (Abingdon, UK), firstly within the Target Validation team identifying new targets to add to the Adaptimmune pipeline. Having cross trained within the Translational team during her time in Target Validation, Robyn moved over to the Tumor profiling team with Translational Sciences in January 2020. As part of the tumor profiling team, Robyn is responsible for analyzing tumor biopsies from Adaptimmune’s clinical trials, and detecting and quantifying the presence of Adaptimmune's SPEAR T-cells. In addition to this, the team is also tasked with understanding the tumor microenvironment within tumor biopsies. This is done through the use of multiplex staining and imaging technologies with spatial immunophenotyping alongside genomics and transcriptomics profiling.